.png){kind=small}
WHAT IT IS
Bremelanotide is a melanocortin receptor agonist that acts through central nervous system pathways involved in sexual desire.
PHYSICIAN-GUIDED SEXUAL HEALTH EVALUATION
PT-141 (Bremelanotide) in Jupiter, Florida
Clear guidance on bremelanotide’s specific FDA-approved use, how it differs from blood-flow medications, and why individualized cardiovascular and sexual-health screening matters.
Timothy Mackey, D.O., Medical Director
Florida License OS9185 · Updated September 2026
A consultation does not guarantee a prescription. Eligible Florida patients may be seen by telemedicine when clinically appropriate.
Timothy Mackey, D.O.Medical Director · Physician-led evaluation and monitoring
PHYSICIANIndividual evaluation
FLORIDALicense OS9185
★★★★★4.9 Google rating
A+BBB rating
MONITORINGOngoing follow-up
Three things to know before deciding
FDA-APPROVED USE
Vyleesi® is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women who meet the labeled criteria.
NOT APPROVED FOR
Men, postmenopausal women, erectile dysfunction, or general sexual-performance enhancement.
CLINICAL CONTEXT
PT-141 and Vyleesi are discussed too broadly online
PT-141 is the common development name for bremelanotide. The FDA-approved product Vyleesi has a narrow indication with specific diagnostic criteria, dosing limits, precautions, and contraindications.
It works differently from sildenafil or tadalafil, which primarily affect blood-flow pathways. That difference does not make it universally appropriate; the underlying cause of sexual symptoms still needs evaluation.
Read the peptide therapy cornerstone guide →Who may need evaluation—and what requires caution
Evaluation should consider
- Whether symptoms fit the labeled HSDD criteria
- Relationship, psychological, medication, and medical contributors
- Blood pressure and cardiovascular history
- Other sexual-health treatment options
Important limitations
- Not indicated to enhance sexual performance
- Not indicated for erectile dysfunction
- Not approved for men or postmenopausal women
- Not a substitute for diagnosing the cause of symptoms
A four-step physician-guided process
Consultation
Review symptoms, goals, medical history, medications, and prior treatment.
Evaluation
Complete a focused exam, records review, and labs when clinically appropriate.
Shared decision
Compare evidence, regulatory status, alternatives, uncertainty, cost, and risk.
Follow-up
If treatment is appropriate, monitor response, side effects, and ongoing need.
SAFETY & MONITORING
What responsible care should address
Bremelanotide can transiently raise blood pressure and reduce heart rate, so screening and dosing limits matter.
- The labeled product is contraindicated in uncontrolled hypertension or known cardiovascular disease.
- Nausea is common. Flushing, headache, vomiting, fatigue, dizziness, and injection-site reactions may occur.
- Focal hyperpigmentation can occur and may not resolve in every patient; risk increases with more frequent use.
- The labeled product should not be used more than once within 24 hours or more than eight times per month, and lack of benefit should prompt reassessment.
Call 911 for a medical emergency. Contact the prescribing clinician promptly for concerning or persistent symptoms.
Put this option in the right clinical context
Women’s hormone care
Explore a broader physician-led evaluation
Explore this page →Peptide therapy guide
Compare approved and investigational therapies
Explore this page →In-person and telemedicine care
NovaGenix serves patients at 609 N. Hepburn Ave., Suite 106, Jupiter, Florida, with telemedicine available to eligible patients throughout Florida.
Clear next steps after evaluation
Cost and availability depend on the medically appropriate option, pharmacy or product, monitoring, and insurance status. The team explains expected costs before treatment begins.
Clear answers, without overpromising
Is PT-141 FDA-approved?
The FDA-approved drug is Vyleesi (bremelanotide) for acquired, generalized HSDD in certain premenopausal women. “PT-141” is often used more broadly online, which can obscure that narrow indication.
Is PT-141 approved for men or erectile dysfunction?
No. Bremelanotide is not FDA-approved for men, erectile dysfunction, or general sexual-performance enhancement.
How is it different from Viagra or Cialis?
Bremelanotide acts through central melanocortin pathways involved in desire. Sildenafil and tadalafil primarily influence penile blood flow. They have different indications, evidence, precautions, and dosing.
Who should not use Vyleesi?
The FDA label contraindicates it in uncontrolled hypertension or known cardiovascular disease. A clinician must also review other risks and whether symptoms meet the indicated diagnosis.
Does a consultation guarantee a prescription?
No. The physician first determines the likely cause of symptoms, whether the labeled or an off-label use is clinically appropriate, and whether risks outweigh potential benefit.
Start with a physician conversation
Discuss your goals, medical history, evidence-based options, and whether this therapy—or a different approach—may be appropriate.
perimen.jpg)
